SCHEMBL3497973

SCHEMBL3497973

CC1CC2(CCCN(C(=O)OC(C)(C)C)C2)C(=O)N1CCN1CCCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
HPGD P15428 1/20 0.36
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
KDM1A O60341 2/20 0.35
CCR5 P51681 2/20 0.35
BACE1 P56817 2/20 0.34
CTSD P07339 1/20 0.34
PIK3R1 P27986 1/20 0.34
PIK3CA P42336 1/20 0.34
PREP P48147 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14222817 0.88 GRIN2B (0.39) USP30HRH3HPGDUSP2SMN1; SMN2
SCHEMBL3498100 0.87 USP30 (0.39) USP30HRH3HPGDUSP2SMN1; SMN2
SCHEMBL14221991 0.86 USP30 (0.39) USP30HRH3HPGDUSP2SMN1; SMN2
SCHEMBL3497614 0.86 USP30 (0.36) USP30HRH3HPGDGRIN2BGRIN2C
SCHEMBL14222282 0.85 USP30 (0.38) USP30HRH3HPGDGRIN2BGRIN2C
SCHEMBL3497703 0.84 BACE1 (0.40) USP30HRH3HPGDGRIN2BGRIN2C
SCHEMBL3495850 0.84 HPGD (0.38) USP30HRH3HPGDGRIN2BGRIN2C
SCHEMBL3496804 0.84 USP30 (0.35) USP30HRH3HPGDGRIN2BGRIN2C
SCHEMBL3498132 0.83 MAPT (0.41) USP30HRH3HPGDGRIN2BGRIN2C
SCHEMBL3497446 0.83 USP30 (0.39) USP30HRH3HPGDGRIN2BGRIN2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC USP30 3125/4885HRH3 4836/4885HPGD 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.